newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

  • Cogent Biosciences, Inc. will participate in the Jefferies Global Healthcare Conference in London on November 19, 2025, at 11:30 a.m. GMT (6:30 a.m. ET).
  • A live webcast of the event will be available on the company's Investors & Media page at investors.cogentbio.com.
  • A replay of the webcast will be posted approximately two hours after the event concludes \& archived for up to 30 days.
  • The company's lead clinical program is bezuclastinib, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation \& other mutations in KIT exon 17.
  • KIT D816V drives systemic mastocytosis, while KIT exon 17 mutations are found in patients with advanced gastrointestinal stromal tumors (GIST).
  • Cogent Biosciences is conducting an ongoing Phase 1 study of its internally discovered FGFR2/3 inhibitor.
  • The company is developing a portfolio of novel targeted therapies for mutations in ErbB2, PI3Kα, KRAS, \& JAK2.
  • Cogent Biosciences is headquartered in Waltham, MA, \& Boulder, CO, with investor information posted on its website \& social media channels.